BeStock  
Stocks › Biotechnology › BCAX

Bicara Therapeutics BCAX

US equityMarket cap rank #3186Biotechnology
$16.42 −$0.14 (-0.85%)
Pre-market · Oct 8, 8:20 am ET · After hours $16.42 0.00%
Open$16.44
Prev close$16.56
Day range$16.25 – $17.11
Volume915.6K
Market cap$1.09B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$59.95M-87.2% YoY
Net profit-$55.44M-102.4% YoY
Diluted EPS-$0.82-64.0% YoY
Free cash flow-$44.27M-73.0% YoY
Operating cash flow-$44.21M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-17.5MSep '24$-21.0MDec '24$-36.8MMar '25$-27.4MJun '25$-36.3MSep '25$-37.4MDec '25$-56.2MMar '26$-55.4MJun '26

Diluted EPS by quarter

-1.60Sep '24-0.39Dec '24-0.68Mar '25-0.50Jun '25-0.67Sep '25-0.68Dec '25-0.93Mar '26-0.82Jun '26

Free cash flow by quarter

$-17.2MSep '24$-30.1MDec '24$-28.1MMar '25$-25.6MJun '25$-29.3MSep '25$-24.1MDec '25$-37.6MMar '26$-44.3MJun '26

Annual revenue

$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-41.0%
Return on assets-38.4%
Return on invested capital-43.1%
Current ratio11.59
Liabilities / assets8.5%
Cash & investments$497.26M
Total debt$0.00
Net cash (debt)$497.26M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $59.95M $60.24M $155.60M $41.12M $40.68M
Selling and Admin Expenses $14.18M $12.74M $30.51M $8.13M $7.70M
-General & Admin Expense $14.18M $12.74M $30.51M $8.13M $7.70M
Research & Development $45.77M $47.50M $125.10M $32.99M $32.98M
Operating Profit -$59.95M -$60.24M -$155.60M -$41.12M -$40.68M
Net Non-Operating Interest Income (Expense) $4.58M $4.08M $17.87M $3.79M $4.39M
Non-Operating Interest Income $4.58M $4.08M $17.87M $3.79M $4.39M
Pretax Profit -$55.38M -$56.16M -$137.73M -$37.33M -$36.29M
Tax $61,000.00 $52,000.00 $217,000.00 $53,000.00 $40,000.00
Net Profit -$55.44M -$56.21M -$137.95M -$37.39M -$36.33M
Profit from Continuing Operations -$55.44M -$56.21M -$137.95M -$37.39M -$36.33M
Net Income to Parent Company -$55.44M -$56.21M -$137.95M -$37.39M -$36.33M
Net Income to Common Stockholders -$55.44M -$56.21M -$137.95M -$37.39M -$36.33M
Basic EPS -$0.82 -$0.93 -$2.52 -$0.68 -$0.67
Diluted EPS -$0.82 -$0.93 -$2.52 -$0.68 -$0.67

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $512.24M $553.60M $430.99M $430.99M $424.69M
Total Current Assets $503.82M $544.92M $422.05M $422.05M $297.37M
Cash and Cash Equivalents & Short-Term Investments $497.26M $539.75M $414.80M $414.80M $290.17M
-Cash and Cash Equivalents $96.60M $323.46M $96.69M $96.69M $171.67M
-Short Term Investments $400.66M $216.29M $318.12M $318.12M $118.49M
Other Current Assets $6.56M $5.16M $7.25M $7.25M $7.21M
Total Non-Current Assets $8.42M $8.68M $8.94M $8.94M $127.32M
Net PPE $1.51M $1.77M $2.03M $2.03M $2.10M
-Gross PPE $1.51M $1.77M $2.03M $2.03M $2.10M
Other Non-Current Assets $6.91M $6.91M $6.91M $6.91M $7.80M
Total Liabilities $43.48M $39.64M $29.54M $29.54M $21.91M
Total Current Liabilities $43.48M $39.34M $28.95M $28.95M $21.03M
Payables $8.46M $7.44M $7.79M $7.79M $3.66M
-Accounts Payable $8.46M $7.44M $7.79M $7.79M $3.66M
Current Accrued Expenses $29.80M $28.85M $15.00M $15.00M $12.28M
Short-Term Debt and Capital Lease Obligation $1.16M $1.14M $1.12M $1.12M $1.10M
-Current Capital Lease Obligation $1.16M $1.14M $1.12M $1.12M $1.10M
Total Non-Current Liabilities $0.00 $301,000.00 $593,000.00 $593,000.00 $880,000.00
Long Term Debt and Capital Lease Obligation $0.00 $301,000.00 $593,000.00 $593,000.00 $880,000.00
-Long Term Capital Lease Obligation $0.00 $301,000.00 $593,000.00 $593,000.00 $880,000.00
Total Equity $468.77M $513.96M $401.45M $401.45M $402.78M
Stockholders' Equity $468.77M $513.96M $401.45M $401.45M $402.78M
Capital Stock $8,000.00 $8,000.00 $7,000.00 $7,000.00 $7,000.00
-Common Stock $8,000.00 $8,000.00 $7,000.00 $7,000.00 $7,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $939.94M $929.37M $760.17M $760.17M $724.49M
Retained Earnings -$470.61M -$415.18M -$358.97M -$358.97M -$321.58M
Gains/Losses Not Affecting Retained Earnings -$567,000.00 -$243,000.00 $243,000.00 $243,000.00 -$136,000.00
Investments and Advances – – – – $117.42M
-Long Term Equity Investment – – – – $117.42M
Convertible preferred securities – – – – $0.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$44.21M -$37.51M -$106.83M -$23.89M -$29.25M
Net cash flow from continuing operations -$44.21M -$37.51M -$106.83M -$23.89M -$29.25M
Net Income from Continuing Operations -$55.44M -$56.21M -$137.95M -$37.39M -$36.33M
Depreciation & Depletion & Amortization $44,000.00 $44,000.00 $105,000.00 $43,000.00 $24,000.00
Other Non-Cash Items $277,000.00 $273,000.00 $895,000.00 $297,000.00 $249,000.00
Change in Working Capital $2.43M $12.19M $14.81M $8.44M $3.16M
-Change in Prepaid Assets -$1.40M $2.09M $5.28M $839,000.00 -$301,000.00
-Change in Payables and Accrued Expense $4.11M $10.37M $10.46M $7.90M $3.78M
-Change in Other Current Liabilities -$277,000.00 -$270,000.00 -$932,000.00 -$292,000.00 -$317,000.00
Net cash flow from investing -$184.99M $100.94M -$318.45M -$82.33M -$236.12M
Net Cash Flow from Continuing Investing Activities -$184.99M $100.94M -$318.45M -$82.33M -$236.12M
Net PPE Purchase and Sale -$60,000.00 -$60,000.00 -$280,000.00 -$238,000.00 -$42,000.00
Net Investment Purchase and Sale -$184.93M $101.00M -$318.17M -$82.09M -$236.08M
Financing Cash Flow $2.33M $163.35M $32.26M $31.23M $436,000.00
Net Cash Flow from Continuing Financing Activities $2.33M $163.35M $32.26M $31.23M $436,000.00
Net Common Stock Issuance $0.00 $161.76M $29.50M $29.50M $0.00
Proceeds from Stock Option Exercised $2.33M $1.58M $2.76M $1.73M $436,000.00
Ending Cash Balance $96.60M $323.46M $96.69M $96.69M $171.67M
Net Change in Cash -$226.86M $226.78M -$393.03M -$74.99M -$264.93M
Beginning Cash Balance $323.46M $96.69M $489.71M $171.67M $436.61M
Free Cash Flow -$44.27M -$37.57M -$107.11M -$24.12M -$29.29M

Discussion

No comments yet — be the first to weigh in on BCAX.

Leave a comment

Scroll to Top